rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Antony A. Riley

Chief Financial Officer

Company insider

Files Form 4 as: Chief Financial Officer, Forte Biosciences; Chief Financial Officer, Krystal Biotech; V.P., Finance, Avanex.

Every Form 4 they filed

In numbers

Trades disclosed
119
Buys
5
Sells
3
Bought
$761K
Sold
$185K
Companies
3
Companies where not an officer
0
First trade
1 Feb 2006
Last trade
27 Aug 2026
Last filed
27 Aug 2026

Companies traded

Where they are an officer
Forte BiosciencesOfficer · Biotechnology · last 27 Aug 20264 buys · 1 sell
KRYS Krystal BiotechOfficer · Biotechnology · last 19 Nov 20191 buy · 0 sells
AvanexOfficer · last 30 Jun 20070 buys · 2 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
27 Aug 2026filed 27 Aug 2026Forte BiosciencesBiotechnologySEC FORM 4 Code U—42,600filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—750filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—60,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—2,976filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—421filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—2,999filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—421filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—2,999filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—1,700filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—2,999filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—14,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—323,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—90,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—22,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—750filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—60,000filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—2,976filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—1,700filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—2,999filing
27 Aug 2026filed 27 Aug 2026Forte Biosciencesoption or derivative · BiotechnologySEC FORM 4 Code D—14,000filing

Sectors

Health Care6
Not placed2

Buys in green, sells in red, by the company’s sector.

Related people

Dino A. RossiDirector · Director at Krystal Biotech, filing Form 4 there in the last year
Daniel JanneyDirector · Director at Krystal Biotech, filing Form 4 there in the last year
Catherine MazzaccoDirector · Director at Krystal Biotech, filing Form 4 there in the last year
Everett Rand SutherlandChief Executive Officer · Director at Krystal Biotech, filing Form 4 there in the last year
Julian S. GangolliDirector · Director at Krystal Biotech, filing Form 4 there in the last year
Krish S. KrishnanPresident and CEO · Also traded KRYS in the last 90 days
Suma KrishnanPresident, R&D · Also traded KRYS in the last 90 days
Donald J. TrumpPresident · Also traded KRYS in the last 90 days